Neuralink Successfully Plants Brain Chip in Clinical Trial
Asia/ Digital/ Updates

Elon Musk’s Neuralink Plants Brain Chip; Human Recipient ‘Recovering Well’

In partnership with:

Neuralink Brain Chip Photo by Website/Neuralink

Tech billionaire Elon Musk's company, Neuralink, has successfully implanted a brain chip into a human patient for the first time in a clinical trial. Elon shared the update on X (formerly Twitter), saying the person who got the brain-computer interface was doing well.

The trial called PRIME Study, got the thumbs-up from the U.S. Food and Drug Administration last May, and they're testing it on people who have trouble moving, like those with quadriplegia.

Recently, the company implanted the said brain-computer interface called “Telepathy” in their first subject. The brain chip is tiny, with threads thinner than a human hair strand, and has more than 1,000 super-small parts.

Musk said this technology “enables control of your phone or computer, and through them almost any device, just by thinking. Initial users will be those who have lost the use of their limbs.”

“Imagine if Stephen Hawking could communicate faster than a speed typist or auctioneer. That is the goal,” Musk added in an X post.

The idea is to make communication lightning-fast, even faster than a speed typist or an auctioneer.

The plan is for this chip to read signals from the brain and send them to an app. That means you can browse the web or play games without lifting a finger – literally! Musk said the early tests are looking good, with "promising neuron spike detection."

Find out more about the Neuralink’s brain chip here.

Get the latest curated content with The Beat Asia's newsletters. Sign up now for a weekly dose of the best stories, events, and deals delivered straight to your inbox. Don't miss out! Click here to subscribe.

This Week's Events In Asia View more

Sign up to receive updates on what's going on in the city. Don't miss out on exciting events, news, and more. Sign up today!

By submitting your email, you agree to our Terms and Privacy Notice
Thank you for subscribing! Click here if you were not redirected.